Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agios Pharmaceuticals (AGIO)

31.52   0.35 (1.12%) 01-25 23:11
Open: 31.04 Pre. Close: 31.17
High: 32.225 Low: 30.63
Volume: 438,653 Market Cap: 1,712M
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 32.275 - 32.429 32.429 - 32.569
Low: 30.257 - 30.433 30.433 - 30.593
Close: 31.227 - 31.519 31.519 - 31.785

Technical analysis

as of: 2022-01-25 4:22:00 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 38.96     One year: 42.14
Support: Support1: 28.96    Support2: 24.09
Resistance: Resistance1: 33.36    Resistance2: 36.08
Pivot: 32.03
Moving Average: MA(5): 30.78     MA(20): 32.49
MA(100): 40.09     MA(250): 47.54
MACD: MACD(12,26): -1.06     Signal(9): -1.03
Stochastic oscillator: %K(14,3): 25.87     %D(3): 14.21
RSI: RSI(14): 44.00
52-week: High: 62.16  Low: 28.96  Change(%): -32.9
Average Vol(K): 3-Month: 614  10-Days: 586

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
AGIO has closed above bottom band by 38.9%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 20 Jan 2022
Is Agios Pharmaceuticals Inc (AGIO) a Stock to Watch After Losing -1.93% This Week? - InvestorsObserver

Thu, 13 Jan 2022
Analysts See 12% Upside For The Holdings of RXL - Nasdaq

Mon, 10 Jan 2022
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases - Yahoo Finance

Sat, 01 Jan 2022
4 Biotechs That Were Winners at ASH - Motley Fool

Tue, 21 Dec 2021
Analysts Just Made A Major Revision To Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue Forecasts - Nasdaq

Tue, 21 Dec 2021
Some Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Estimates - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 54
Shares Float (M) 54
% Held by Insiders 1.20
% Held by Institutions 113.73
Shares Short (K) 5,570
Shares Short P. Month (K) 7,410

Stock Financials

EPS 24.950
EPS Est This Year -7.080
EPS Est Next Year -7.370
Book Value (p.s.) 25.490
Profit Margin 788.25
Operating Margin -166.91
Return on Assets (ttm) -17.3
Return on Equity (ttm) -36.3
Qtrly Rev. Growth
Gross Profit (p.s.) -3.076
Sales Per Share 3.741
EBITDA (p.s.) -6.064
Qtrly Earnings Growth
Operating Cash Flow (M) -373
Levered Free Cash Flow (M) -138

Stock Valuations

PE Ratio 1.26
PEG Ratio
Price to Book value 1.24
Price to Sales 8.42
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.